Refludan

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved March 1998

Specific Treatments:

heparin-induced thrombocytopenia type II

Therapeutic Areas

General Information

Refludan has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT type II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood's platelet count, leading to an increased risk of severe thromboembolic complications.